News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e... Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it
News Amgen pays Kyowa $400m upfront for OX40 eczema drug Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.